Navigation Links
Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
Date:4/20/2012

SEATTLE, April 20, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported financial results and recent accomplishments for the first quarter of 2012.

First Quarter Financial ResultsFor the quarter ended March 31, 2012, total operating expenses were $18.1 million compared to $20.1 million for the same period in 2011. Net loss attributable to common shareholders decreased 66% to $17.4 million ($0.09 per share) for the quarter ended March 31, 2012 compared to a net loss attributable to common shareholders of $51.0 million ($0.35 per share) for the same period in 2011. The decrease in net loss attributable to CTI's common shareholders is primarily due to a decrease in deemed dividends and total operating expenses. CTI had approximately $27.4 million in cash and cash equivalents as of March 31, 2012.

Recent Highlights

  • In February 2012, the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP") granted a positive opinion for conditional approval of CTI's MAA for Pixuvri as monotherapy for the treatment of adult patients with multiple relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma ("NHL").
  • In April 2012, CTI entered into an agreement to acquire a highly selective JAK2 inhibitor, pacritinib, which is a phase 3 candidate for treating patients with myelofibrosis ("MF").
  • "With potential approval of our MAA for Pixuvri in the E.U. to treat adult patients with multiple relapsed or refractory aggressive B-cell non-Hodgkin lymphoma and tosedostat gearing up to initiate a pivotal phase 3 trial in relapsed or refractory acute myeloid leukemia/myelodysplastic syndromes ("MDS") later this year, the agreement to acquire pacritinib, a highly selective JAK2 inhibitor, rounds out our novel late stage oncology drug portfolio placing us in a select group of biotech companies.  Our oncology drug portfolio now spans across
    '/>"/>

    SOURCE Cell Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
    2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
    3. Cell Therapeutics, Inc. Announces Reverse Stock Split
    4. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
    5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
    6. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
    7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
    8. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
    9. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
    10. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
    11. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... to release financial results for the first quarter of ... market close in the US.  The ... ET on Friday, August 29, 2014 to discuss its ... Company,s recent developments, followed by a question and answer ...
    (Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
    (Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
    (Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
    Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3
    ... you doing to become a better husband or wife, daughter ... to turn my e-mail into a confessional. I've just been ... who have been making that relationship work, it's funny how ... Sounds like some idealized family. , ,"Oh great!" you're thinking. ...
    ... Madison, Wis. - One of Wisconsin's most prominent ... its name changed. This move will result in a ... potential opportunites for the state's life science industry, increase ... for the firm's investors. , , Genzyme Corp. , ...
    ... old Institute of Paper Chemistry might have left Appleton more ... feel the void. , ,Organizers of the new ... void Wednesday with the PTTC's grand opening in downtown Green ... rolling out more than 6.4 million tons of paper and ...
    Cached Biology Technology:Taking your work home 2Taking your work home 3Genzyme acquistion of Bone Care approved, significant impact forecast 2Genzyme acquistion of Bone Care approved, significant impact forecast 3Genzyme acquistion of Bone Care approved, significant impact forecast 4Paper technology transfer center opens in Green Bay 2Paper technology transfer center opens in Green Bay 3
    (Date:8/21/2014)... the pancreas digesting itself resulting in severe abdominal pain, ... around 20,000 patients are diagnosed with the disease resulting ... treatment is restricted to intravenous fluid and nutritional support. ... Life Sciences, who led the research, said "The major ... stones and excessive alcohol intake combined with a high ...
    (Date:8/20/2014)... 20, 2014 /CNW/ -  Issue Serious ... quickly become life threatening for some children.    ... million Canadians have food allergies and this number may be ... children are estimated to have food allergies.  ... irritations and hives to breathing difficulties and loss of consciousness. ...
    (Date:8/20/2014)... Institutes of Health has awarded the Oklahoma Medical Research ... research on anthrax and the bacteria,s effects on humans. ... Ph.D., and his colleagues have studied the human immune ... Centers for Human Immunology. The original funding came soon ... the heels of the terrorist attacks of Sept. 11, ...
    Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3$14.5 million grant awarded to continue anthrax studies 2
    ... team of engineers and scientists at the University of British ... the eye for controlled and on-demand release of drugs to ... the leading cause of vision loss among patients with diabetes. ... cells in the retina, which in its advanced stages can ...
    ... new biological evidence suggesting that the brain works differently ... own race than when memorizing a face from another ... to measure brain activity -- sheds light on a ... the most replicated psychology findings, the other-race effect finds ...
    ... onset of puberty is a critical moment for reaching ... are particularly high in countries where the HIV/AIDS epidemic ... Yet to date, the healthcare community in low-resource countries ... efforts on young women who are older and of ...
    Cached Biology News:UBC researchers invent new drug delivery device to treat diabetes-related vision loss 2Clues to why 'they' all look alike 2Clues to why 'they' all look alike 3Clues to why 'they' all look alike 4Girl's Puberty Book Project provides an international model for promoting female health in Africa 2Girl's Puberty Book Project provides an international model for promoting female health in Africa 3
    ... RNase H- Reverse Transcriptase ... version of SuperScript™ II ... SuperScript™ II it synthesizes ... from single-stranded RNA DNA ...
    versican (H-56)...
    ... Heraeus HERAcell is the ideal CO2 incubator ... of ova or embryos at or near ... to provide everything needed to protect and ... Safe and stable incubation conditions ensure optimum ...
    ... presents PsiPort Mass Directed Auto Purification ... data acquisition system designed for automated ... life science and pharmaceutical discovery programs. ... to simplify high throughput mass directed ...
    Biology Products: